Halozyme Therapeutics' GAAP net income for 3 months of 2022 was $60.108 million, up 2.2 times from $27.895 million in the previous year. Revenue increased 31.7% to $117.279 million compared to $89.022 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept